Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study
Gastric acid secretion inhibitors such as proton pump inhibitors (PPIs) and vonoprazan may change the duration of treatment with bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, for cancer. However, there are no data on this prolongation effect. Here, we aimed to determine whether...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental medicine 2023-10, Vol.23 (6), p.2799-2804 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2804 |
|---|---|
| container_issue | 6 |
| container_start_page | 2799 |
| container_title | Clinical and experimental medicine |
| container_volume | 23 |
| creator | Yagi, Kenta Maruo, Akinori Ishida, Shunsuke Aizawa, Fuka Ushio, Soichiro Sakaguchi, Satoshi Kajizono, Makoto Niimura, Takahiro Goda, Mitsuhiro Hamano, Hirofumi Izawa-Ishizawa, Yuki Zamami, Yoshito Ishizawa, Keisuke |
| description | Gastric acid secretion inhibitors such as proton pump inhibitors (PPIs) and vonoprazan may change the duration of treatment with bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, for cancer. However, there are no data on this prolongation effect. Here, we aimed to determine whether the use of PPIs or vonoprazan in patients with cancer receiving bevacizumab affected the duration of bevacizumab treatment. This observational study was conducted at two national university hospitals in Japan and involved 222 patients using oral PPIs (
N
= 190) or vonoprazan (
N
= 32) at the start of bevacizumab treatment between January 2015 and December 2018. Patients who received only one course of bevacizumab were excluded. The primary endpoint was the duration of bevacizumab treatment. The duration of bevacizumab treatment varied significantly between the PPI and vonoprazan groups. For cancer types other than colorectal cancer (breast, lung, brain, and ovarian cancers), the median duration of treatment was 217 days (
p
|
| doi_str_mv | 10.1007/s10238-023-01008-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2773125026</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2773125026</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-a131ddc8e97775f2dbeee0a945764432cf94a313512ba1c672a5e849ad7306863</originalsourceid><addsrcrecordid>eNp9kU9PHSEUxYnRqFW_QBcNiZtupvJnGBh3xqhtYtJNuyYMc1HMG5gC85Lnpy_PZ1vjopvLDfzOudwchD5S8oUSIi8yJYyrppaG1AvV0D10TEVPm14wtf-mP0Ifcn4ihArFySE64p3ktRPHKN04B7ZkHB1exxDnZJ5NwCaMeE6xxIDnZZqxD49-8CWmCgZcHgGDc94au9kKB1gb65-XyQyX2OBpWRVvIZQEOEFJMc91hF8DzmUZN6fowJlVhrPX8wT9vL35cf21uf9-9-366r6xvGelMZTTcbQKeimlcGwcAICYvhWya1vOrOtbwykXlA2G2k4yI0C1vRklJ53q-An6vPOti_xaIBc9-WxhtTIB4pI1k5JTJgjboufv0Ke4pFB_p5mSRDKhRFsptqNsXSkncHpOfjJpoynR20T0LhFdi35JRNMq-vRqvQwTjH8lfyKoAN8BuT6FB0j_Zv_H9jejgpcy</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2870725854</pqid></control><display><type>article</type><title>Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study</title><source>SpringerLink Journals</source><creator>Yagi, Kenta ; Maruo, Akinori ; Ishida, Shunsuke ; Aizawa, Fuka ; Ushio, Soichiro ; Sakaguchi, Satoshi ; Kajizono, Makoto ; Niimura, Takahiro ; Goda, Mitsuhiro ; Hamano, Hirofumi ; Izawa-Ishizawa, Yuki ; Zamami, Yoshito ; Ishizawa, Keisuke</creator><creatorcontrib>Yagi, Kenta ; Maruo, Akinori ; Ishida, Shunsuke ; Aizawa, Fuka ; Ushio, Soichiro ; Sakaguchi, Satoshi ; Kajizono, Makoto ; Niimura, Takahiro ; Goda, Mitsuhiro ; Hamano, Hirofumi ; Izawa-Ishizawa, Yuki ; Zamami, Yoshito ; Ishizawa, Keisuke</creatorcontrib><description>Gastric acid secretion inhibitors such as proton pump inhibitors (PPIs) and vonoprazan may change the duration of treatment with bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, for cancer. However, there are no data on this prolongation effect. Here, we aimed to determine whether the use of PPIs or vonoprazan in patients with cancer receiving bevacizumab affected the duration of bevacizumab treatment. This observational study was conducted at two national university hospitals in Japan and involved 222 patients using oral PPIs (
N
= 190) or vonoprazan (
N
= 32) at the start of bevacizumab treatment between January 2015 and December 2018. Patients who received only one course of bevacizumab were excluded. The primary endpoint was the duration of bevacizumab treatment. The duration of bevacizumab treatment varied significantly between the PPI and vonoprazan groups. For cancer types other than colorectal cancer (breast, lung, brain, and ovarian cancers), the median duration of treatment was 217 days (
p
< 0.05) and was longer in the vonoprazan group than in the PPI group. However, for colorectal cancer, the median duration of bevacizumab treatment was 147 days longer in the PPI group than in the vonoprazan group. Selection of appropriate gastric acid secretion inhibitors may improve the therapeutic efficacy of anti-VEGF drugs, including bevacizumab. Oestrogen is a key regulator of this effect and may be responsible for the varying association between PPI or vonoprazan administration and the difference in bevacizumab treatment duration between colon cancer and other cancer types.</description><identifier>ISSN: 1591-9528</identifier><identifier>ISSN: 1591-8890</identifier><identifier>EISSN: 1591-9528</identifier><identifier>DOI: 10.1007/s10238-023-01008-1</identifier><identifier>PMID: 36738305</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Bevacizumab ; Colon cancer ; Colorectal cancer ; Colorectal carcinoma ; Estrogens ; Gastric juice ; Hematology ; Internal Medicine ; Lung cancer ; Medicine ; Medicine & Public Health ; Monoclonal antibodies ; Oncology ; Ovarian cancer ; Patients ; Proton pump inhibitors ; Secretion ; Targeted cancer therapy ; Vascular endothelial growth factor</subject><ispartof>Clinical and experimental medicine, 2023-10, Vol.23 (6), p.2799-2804</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c392t-a131ddc8e97775f2dbeee0a945764432cf94a313512ba1c672a5e849ad7306863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10238-023-01008-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10238-023-01008-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36738305$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yagi, Kenta</creatorcontrib><creatorcontrib>Maruo, Akinori</creatorcontrib><creatorcontrib>Ishida, Shunsuke</creatorcontrib><creatorcontrib>Aizawa, Fuka</creatorcontrib><creatorcontrib>Ushio, Soichiro</creatorcontrib><creatorcontrib>Sakaguchi, Satoshi</creatorcontrib><creatorcontrib>Kajizono, Makoto</creatorcontrib><creatorcontrib>Niimura, Takahiro</creatorcontrib><creatorcontrib>Goda, Mitsuhiro</creatorcontrib><creatorcontrib>Hamano, Hirofumi</creatorcontrib><creatorcontrib>Izawa-Ishizawa, Yuki</creatorcontrib><creatorcontrib>Zamami, Yoshito</creatorcontrib><creatorcontrib>Ishizawa, Keisuke</creatorcontrib><title>Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study</title><title>Clinical and experimental medicine</title><addtitle>Clin Exp Med</addtitle><addtitle>Clin Exp Med</addtitle><description>Gastric acid secretion inhibitors such as proton pump inhibitors (PPIs) and vonoprazan may change the duration of treatment with bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, for cancer. However, there are no data on this prolongation effect. Here, we aimed to determine whether the use of PPIs or vonoprazan in patients with cancer receiving bevacizumab affected the duration of bevacizumab treatment. This observational study was conducted at two national university hospitals in Japan and involved 222 patients using oral PPIs (
N
= 190) or vonoprazan (
N
= 32) at the start of bevacizumab treatment between January 2015 and December 2018. Patients who received only one course of bevacizumab were excluded. The primary endpoint was the duration of bevacizumab treatment. The duration of bevacizumab treatment varied significantly between the PPI and vonoprazan groups. For cancer types other than colorectal cancer (breast, lung, brain, and ovarian cancers), the median duration of treatment was 217 days (
p
< 0.05) and was longer in the vonoprazan group than in the PPI group. However, for colorectal cancer, the median duration of bevacizumab treatment was 147 days longer in the PPI group than in the vonoprazan group. Selection of appropriate gastric acid secretion inhibitors may improve the therapeutic efficacy of anti-VEGF drugs, including bevacizumab. Oestrogen is a key regulator of this effect and may be responsible for the varying association between PPI or vonoprazan administration and the difference in bevacizumab treatment duration between colon cancer and other cancer types.</description><subject>Bevacizumab</subject><subject>Colon cancer</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Estrogens</subject><subject>Gastric juice</subject><subject>Hematology</subject><subject>Internal Medicine</subject><subject>Lung cancer</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Monoclonal antibodies</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><subject>Patients</subject><subject>Proton pump inhibitors</subject><subject>Secretion</subject><subject>Targeted cancer therapy</subject><subject>Vascular endothelial growth factor</subject><issn>1591-9528</issn><issn>1591-8890</issn><issn>1591-9528</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kU9PHSEUxYnRqFW_QBcNiZtupvJnGBh3xqhtYtJNuyYMc1HMG5gC85Lnpy_PZ1vjopvLDfzOudwchD5S8oUSIi8yJYyrppaG1AvV0D10TEVPm14wtf-mP0Ifcn4ihArFySE64p3ktRPHKN04B7ZkHB1exxDnZJ5NwCaMeE6xxIDnZZqxD49-8CWmCgZcHgGDc94au9kKB1gb65-XyQyX2OBpWRVvIZQEOEFJMc91hF8DzmUZN6fowJlVhrPX8wT9vL35cf21uf9-9-366r6xvGelMZTTcbQKeimlcGwcAICYvhWya1vOrOtbwykXlA2G2k4yI0C1vRklJ53q-An6vPOti_xaIBc9-WxhtTIB4pI1k5JTJgjboufv0Ke4pFB_p5mSRDKhRFsptqNsXSkncHpOfjJpoynR20T0LhFdi35JRNMq-vRqvQwTjH8lfyKoAN8BuT6FB0j_Zv_H9jejgpcy</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Yagi, Kenta</creator><creator>Maruo, Akinori</creator><creator>Ishida, Shunsuke</creator><creator>Aizawa, Fuka</creator><creator>Ushio, Soichiro</creator><creator>Sakaguchi, Satoshi</creator><creator>Kajizono, Makoto</creator><creator>Niimura, Takahiro</creator><creator>Goda, Mitsuhiro</creator><creator>Hamano, Hirofumi</creator><creator>Izawa-Ishizawa, Yuki</creator><creator>Zamami, Yoshito</creator><creator>Ishizawa, Keisuke</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20231001</creationdate><title>Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study</title><author>Yagi, Kenta ; Maruo, Akinori ; Ishida, Shunsuke ; Aizawa, Fuka ; Ushio, Soichiro ; Sakaguchi, Satoshi ; Kajizono, Makoto ; Niimura, Takahiro ; Goda, Mitsuhiro ; Hamano, Hirofumi ; Izawa-Ishizawa, Yuki ; Zamami, Yoshito ; Ishizawa, Keisuke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-a131ddc8e97775f2dbeee0a945764432cf94a313512ba1c672a5e849ad7306863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Bevacizumab</topic><topic>Colon cancer</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Estrogens</topic><topic>Gastric juice</topic><topic>Hematology</topic><topic>Internal Medicine</topic><topic>Lung cancer</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Monoclonal antibodies</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><topic>Patients</topic><topic>Proton pump inhibitors</topic><topic>Secretion</topic><topic>Targeted cancer therapy</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yagi, Kenta</creatorcontrib><creatorcontrib>Maruo, Akinori</creatorcontrib><creatorcontrib>Ishida, Shunsuke</creatorcontrib><creatorcontrib>Aizawa, Fuka</creatorcontrib><creatorcontrib>Ushio, Soichiro</creatorcontrib><creatorcontrib>Sakaguchi, Satoshi</creatorcontrib><creatorcontrib>Kajizono, Makoto</creatorcontrib><creatorcontrib>Niimura, Takahiro</creatorcontrib><creatorcontrib>Goda, Mitsuhiro</creatorcontrib><creatorcontrib>Hamano, Hirofumi</creatorcontrib><creatorcontrib>Izawa-Ishizawa, Yuki</creatorcontrib><creatorcontrib>Zamami, Yoshito</creatorcontrib><creatorcontrib>Ishizawa, Keisuke</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yagi, Kenta</au><au>Maruo, Akinori</au><au>Ishida, Shunsuke</au><au>Aizawa, Fuka</au><au>Ushio, Soichiro</au><au>Sakaguchi, Satoshi</au><au>Kajizono, Makoto</au><au>Niimura, Takahiro</au><au>Goda, Mitsuhiro</au><au>Hamano, Hirofumi</au><au>Izawa-Ishizawa, Yuki</au><au>Zamami, Yoshito</au><au>Ishizawa, Keisuke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study</atitle><jtitle>Clinical and experimental medicine</jtitle><stitle>Clin Exp Med</stitle><addtitle>Clin Exp Med</addtitle><date>2023-10-01</date><risdate>2023</risdate><volume>23</volume><issue>6</issue><spage>2799</spage><epage>2804</epage><pages>2799-2804</pages><issn>1591-9528</issn><issn>1591-8890</issn><eissn>1591-9528</eissn><abstract>Gastric acid secretion inhibitors such as proton pump inhibitors (PPIs) and vonoprazan may change the duration of treatment with bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, for cancer. However, there are no data on this prolongation effect. Here, we aimed to determine whether the use of PPIs or vonoprazan in patients with cancer receiving bevacizumab affected the duration of bevacizumab treatment. This observational study was conducted at two national university hospitals in Japan and involved 222 patients using oral PPIs (
N
= 190) or vonoprazan (
N
= 32) at the start of bevacizumab treatment between January 2015 and December 2018. Patients who received only one course of bevacizumab were excluded. The primary endpoint was the duration of bevacizumab treatment. The duration of bevacizumab treatment varied significantly between the PPI and vonoprazan groups. For cancer types other than colorectal cancer (breast, lung, brain, and ovarian cancers), the median duration of treatment was 217 days (
p
< 0.05) and was longer in the vonoprazan group than in the PPI group. However, for colorectal cancer, the median duration of bevacizumab treatment was 147 days longer in the PPI group than in the vonoprazan group. Selection of appropriate gastric acid secretion inhibitors may improve the therapeutic efficacy of anti-VEGF drugs, including bevacizumab. Oestrogen is a key regulator of this effect and may be responsible for the varying association between PPI or vonoprazan administration and the difference in bevacizumab treatment duration between colon cancer and other cancer types.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>36738305</pmid><doi>10.1007/s10238-023-01008-1</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1591-9528 |
| ispartof | Clinical and experimental medicine, 2023-10, Vol.23 (6), p.2799-2804 |
| issn | 1591-9528 1591-8890 1591-9528 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2773125026 |
| source | SpringerLink Journals |
| subjects | Bevacizumab Colon cancer Colorectal cancer Colorectal carcinoma Estrogens Gastric juice Hematology Internal Medicine Lung cancer Medicine Medicine & Public Health Monoclonal antibodies Oncology Ovarian cancer Patients Proton pump inhibitors Secretion Targeted cancer therapy Vascular endothelial growth factor |
| title | Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T01%3A02%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20vonoprazan%20and%20proton%20pump%20inhibitors%20on%20the%20efficacy%20of%20bevacizumab:%20a%20multicentre%20retrospective%20study&rft.jtitle=Clinical%20and%20experimental%20medicine&rft.au=Yagi,%20Kenta&rft.date=2023-10-01&rft.volume=23&rft.issue=6&rft.spage=2799&rft.epage=2804&rft.pages=2799-2804&rft.issn=1591-9528&rft.eissn=1591-9528&rft_id=info:doi/10.1007/s10238-023-01008-1&rft_dat=%3Cproquest_cross%3E2773125026%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2870725854&rft_id=info:pmid/36738305&rfr_iscdi=true |